At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 233 enrolled
Drug / intervention
LY3473329 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events
In Brief
A Phase 2 clinical trial evaluating LY3473329 and Placebo for Lipoprotein Disorder. Completed, enrolled 233 participants across 42 sites in 8 countries.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLipoprotein Disorder
CountriesAustralia, Brazil, China, Germany, Hungary, Japan, Netherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedOct 2022
Enrollment StartNov 2022
Primary CompletionMar 2024
TodayJul 2026
First PostedOct 3, 2022
Enrollment StartNov 24, 2022
Primary CompletionMar 14, 2024
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 3.7 years ago
Interventions
LY3473329drug
Administered orally
Placebodrug
Administered orally